| Ytd | 34.92% | |
| 1y | 43.86% |
| Open | 31.49 | Prev Close | 31.49 | Low | 31.49 | High | 31.49 | Mkt Cap | 3.85B |
| Vol | 0.00 | Avg Vol | 3.01M | EPS | 2.56 | P/E | 12.30 | Forward P/E | 9.05 |
| Beta | 0.74 | Short Ratio | 4.11 | Inst. Own | 90.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 31.26 | 200-d Avg | 25.41 | 1yr Est | 31.67 |
California State Teachers Retirement System raised its holdings in Catalyst Pharmaceuticals, Inc. (N
Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker C
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadersh
Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angel
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immun
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 202
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Cataly
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.79 per share, beating the Zack
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and
Major M&A deals this week include: Gamestop's proposal to acquire eBay, Long Lake buys Ameri
Jim Cramer recommended holding Texas Instruments (TXN) on CNBC's Mad Money, supported by an anal
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Stanley Black & Decker, Inc.
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earni
Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earn
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly
Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to repor
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly
Here's a roundup of top developments in the biotech space over the last 24 hours:
Before 10 a.m. ET on Thursday, 145 companies set new 52-week highs.
Friday's morning session saw 160 companies set new 52-week highs.
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its fir
Catalyst Pharmaceutical Partners Granted Orphan Medicinal Product Designation in European Union for